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Abstract
Background: It has been shown that epidermal growth factor receptor (EGFR) mutation status is associated with
5-fluorouracil (5-FU) sensitivity in non-small-cell lung cancer (NSCLC). However, the relationship between EGFR
mutation status and dihydropyrimidine dehydrogenase (DPD), a 5-FU degrading enzyme, is unknown.
Methods: We elucidated the crosstalk among the EGFR signal cascade, the DPD gene (DPYD), and DPD protein
expression via the transcription factor Sp1 and the effect of EGFR mutation status on the crosstalk.
Results: In the PC9 (exon19 E746-A750) study, EGF treatment induced up-regulation of both Sp1 and DPD; gefitinib,
an EGFR-tyrosine kinase inhibitor (EGFR-TKI), and mithramycin A, a specific Sp-1 inhibitor, suppressed them. Among
EGFR-mutated (PC9, HCC827; exon19 E746-A750 and H1975; exon21 L858R, T790M, gefitinib resistant) and
-non-mutated (H1437, H1299) cell lines, EGF administration increased DPYD mRNA expression only in mutated cells
(p < 0.05). Accordingly, gefitinib inhibited DPD protein expression only in PC9 and HCC827 cells, and mithramycin A
inhibited it in EGFR-mutated cell lines, but not in wild-type. FU treatment decreased the level of cell viability more in
gefitinib-treated EGFR-TKI sensitive cell lines. Further, combination treatment of FU and mithramycin A suppressed cell
viability even in a gefitinib resistant cell line.
Conclusions: The EGFR signal cascade regulates DPD expression via Sp1 in EGFR mutant cells. These results might be a
step towards new therapies targeting Sp1 and DPD in NSCLC with different EGFR mutant status.
Keywords: Non-small-cell lung cancer, Sp1, Dihydropyrimidine dehydrogenase, Epidermal growth factor receptor
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Background
The epidermal growth factor receptor (EGFR) is highly
expressed in cancer cells, including non-small-cell lung
cancer (NSCLC). Molecular-targeted therapy by EGFR
tyrosine kinase inhibitor (EGFR-TKI) has altered the
treatment regimen of NSCLC. In vitro and clinical
studies have indicated predictive factors associated with
the response and survival benefit of EGFR-TKI,
including gefitinib, and higher response populations are
observed in East Asians, non-smokers, females, and
adenocarcinoma (ADC) patients [1–4]. A combination
analysis of a Japanese phase II study found that NSCLC
patients with EGFR mutations have higher response
rates for EGFR-TKI [5]. Several randomized studies have
also revealed that reversible EGFR-TKIs such as erlotinib
and gefitinib are superior to standard chemotherapy
with regard to progression-free survival, as well as
progression-free survival in patients with NSCLC with
EGFR sensitive mutations [6–10]. However, primary or
acquired resistance limits the therapeutic success of
these targeted agents [11, 12]. An irreversible inhibitor
* Correspondence: nagayasu@nagasaki-u.ac.jp
1Division of Surgical Oncology, Department of Surgery, Nagasaki University
Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki
852-8501, Japan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tominaga et al. BMC Cancer  (2016) 16:354 
DOI 10.1186/s12885-016-2392-0
of afatinib has been developed to confer sustained disease
control in ErbB-dependent cancers. A large LUX-Lung 3
phase III trial recently demonstrated that afatinib is clearly
superior to the most effective platinum doublet in patients
with EGFR mutation-positive lung cancer [13]. Thus, trials
testing the potential efficacy of afatinib for reversible
EGFR-TKI resistant NSCLCs are ongoing.
Anti-metabolite drugs, such as the fluoropyrimidine
anti-cancer agent 5-fluorouracil (5-FU) and pemetrexed,
have been used worldwide for chemotherapy with
several types of solid tumor. Enzymes that participate in
the pyrimidine metabolic pathway, including thymidylate
synthase (TS), orotate phosphoribosyltransferase (OPRT),
and dihydropyrimidine dehydrogenase (DPD), play an
important role in FU sensitivity [14]. For pemetrexed, high
TS has been shown to be correlated with resistance based
on clinical and cell culture studies [15]. DPD is the initial
enzyme in the pyrimidine catabolic pathway, and about
80 % of administered FU is rapidly catabolized in the liver
[16–18]. Previously, the use of FU was thought to be
inappropriate for lung cancer therapy, because the lung
contains high levels of DPD, which is known to degrade
FU. However, some DPD inhibitory fluoropyrimidines
(DIF) have been developed which avoid the problem of
degradation by DPD [19–22].
In 2007, Suehisa and colleagues showed that the IC50s
of EGFR mutant cells to FU were higher than those of
wild-type cells, indicating that EGFR wild-type cells are
more sensitive to FU than mutant cells [23]. In our
previous immunohistochemical staining for DPD in
NSCLC specimens, high DPD expression was signifi-
cantly correlated with EGFR mutation status and adeno-
carcinoma with a lepidic pattern [24]. Cell-based and
histological studies led us to believe that EGFR mutation
status might affect the sensitivity to FU due to high
DPD expression in cells. Because EGFR-mutated NSCLC
shows high DPD expression while EGFR wild-type
shows low DPD expression, which correlate with EGFR-
TKI and 5-FU sensitivity, we considered that there is a
biological rationale for studying the interplay between
EGFR mutation status and DPD expression for drug
selection and personalized chemotherapy.
Accordingly, there are some molecular clues that ex-
plain the correlation between the EGFR cascade and DPD
expression. DPYD, the DPD gene, has two transcriptional
regulatory regions, and the binding of transcription factor
specificity protein 1 (Sp1) to the DPYD promoter region is
implicated in DPD constitutive expression [25, 26]. Lee
and colleagues reported that Sp1 is present downstream
of the EGFR-ERK1/2 signal cascade [27]. These studies
indicate the possibility that Sp1 intermediates the EGFR-
ERK1/2 signal cascade and DPD expression.
In the present study, we examined the signaling
cascade from EGFR to DPD in vitro. To examine signal
cascade regulation, we treated NSCLC cell lines with EGFR
signal activator (EGF) or inhibitors (gefitinib, mithramycin
A). In addition, we investigated whether EGFR mutation




Gefitinib was purchased from Tocris Bioscience (Bristol,
UK). Mithramycin A, a specific Sp1 transcription factor
inhibitor, was obtained from SERVA Electrophoresis GmbH
(Heidelberg, Germany). EGF and antibodies against ERK1/
2, pERK1/2 (Phospho-Thr202/Tyr204), Sp1, and DPD were
purchased from Cell Signaling (Beverly, MA, USA). β-actin
(loading control) was from Abcam (Cambridge, UK).
Lung cancer cell lines and culture conditions
Human lung adenocarcinoma cell line PC9 (exon19 E746-
A750) was obtained from Immuno-Biological Laboratories
(Gunma, Japan). NCI-H1975 (exon21 L858R, T790M),
NCI-H1437 (wild-type), and NCI-H1299 (wild-type) were
obtained from the American Type Culture Collection
(Manassas, VA, USA). HCC827 was kindly provided by Dr.
Isamu Okamoto (Kyushu University Hospital). These cell
lines were incubated in a humid atmosphere containing
95 % air and 5 % CO2 in Roswell Park Memorial Institute
(RPMI) media (Invitrogen Japan, Tokyo, Japan). The media
contained 10 % fetal bovine serum, 1 % penicillin-
streptomycin (Nacalai Tesque, Kyoto, Japan), and 2 mM L-
glutamine (Invitrogen Japan).
Quantitative polymerase chain reaction and mRNA
expression
RNA in cultured cells was extracted using an RNeasy
Mini Kit (QIAGEN, Tokyo, Japan), and cDNA was
produced using PrimeScript RT Master Mix (Takara,
Shiga, Japan). The sequences of PCR primers for mRNA
in DPD, Sp1, and β-actin were as follows: DPD forward,
5’-GTTGTGGCTATGATTGATGA-3’, and reverse, 5’-
ATTCACAGATAAGGGTACGC-3’; Sp1 forward, 5’-
TTGAAAAAGGAGTTGGTGGC-3’, and reverse, 5’-
TGCTGGTTCTGTAAGTTGGG-3’; β-actin forward, 5’-
GCAAAGACCTGTACGCCAAC-3’, and reverse, 5’-
CTAGAAGCATTTGCGGTGGA-3’. PCR reactions were
performed with 20 ng of cDNA with LightCycler 480
SYBR Green I Master (Roche Molecular Biochemicals,
Indianapolis, IN, USA). Quantitative RT-PCR was per-
formed on a Roche LightCycler 480 system (Roche Mo-
lecular Biochemicals). Quantification data were analyzed
with the LightCycler analysis software (Roche Molecular
Biochemicals).
Tominaga et al. BMC Cancer  (2016) 16:354 Page 2 of 9
Western blot analysis
Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA)
was used to collect whole cell lysates. Proteins were
fractionated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) using 8 % gradient gels.
The protein was blotted onto a polyvinylidene difluoride
membrane. After blocking with Blocking One-P (Nacalai
Tesque) for 20 min, the membrane was incubated over-
night at 4 °C with primary antibodies against ERK1/2,
pERK1/2, Sp1, DPD, and β-actin (loading control),
followed by horseradish peroxidase-conjugated goat anti-
rabbit IgG (Amersham, Buckinghamshire, UK). Immuno-
labeled protein was visualized using a Luminescent Image
Analyzer LAS-1000plus (Fujifilm, Tokyo, Japan) after in-
cubation with Chemi-Lumi One Super (Nacalai Tesque).
EGF administration
To examine the relationship between DPD expression
and the EGFR signaling cascade, we administered vary-
ing concentrations of EGF (0 to 10 ng/ml). After we
grew NSCLC cells to 80 % confluence, culture medium
was replaced with serum-free medium, and we then
administered each concentration of EGF. After add-
itional incubation at 37 °C for 20 min, cell lysates were
extracted.
Growth inhibition assay
The growth inhibitory activities of gefitinib and mithramy-
cin A were evaluated by the cell proliferation reagent
WST-1 (Roche Diagnostic GmbH, Mannheim, Germany).
NSCLC cell lines were seeded in 96-well plates at a
density of 105/well with culture medium for 24 h. The
cells were exposed to various concentrations of FU and
gefitinib/mithramycin A for another 24 h at 37 °C in a 5 %
CO2 atmosphere. After that, WST-1 was added to each
well and incubated for 2 h at 37 °C before measuring
absorbance at 490 nm with a Multiskan JX Spectrum
instrument (Thermo Labsystems, Boston, MA, USA).
Sp1 DNA binding assays
Cells were treated by gefitinib and mithramycin A, and
nuclear proteins were extracted. Ten micrograms of
nuclear extract were examined for Sp1 DNA binding
activity by using a Trans AM Sp1 Kit (Active Motif ),
and control and treatment groups were compared. The
absorbance was measured at 450 nm by a Multiskan JX
Spectrum instrument (Thermo Labsystems).
Apoptosis assay by DNA fragmentation
Apoptosis was evaluated by enzyme-linked immunosorb-
ent assay (ELISA) using a Cell Death Detection ELISAPlus
Kit (Roche Applied Science, Mannheim, Germany). The
amounts of mononucleosomes and oligonucleosomes
generated from the apoptotic cells were quantified using
monoclonal antibodies directed against histones and DNA
by ELISA. Absorbance was measured at 405 nm by a
Multiskan JX Spectrum instrument (Thermo Labsystems).
Statistical analysis
Data from WST-1 assays and real-time RT-PCR are
expressed as means ± S.D. The statistical significance of
differences among the five cell lines was examined by
Tukey-Kramer analysis. Student’s t-test and Dunnett’s
multiple comparison were used to analyze associations
between the control and experimental groups in each
cell line. For all experiments, a two-sided p-value less
than 0.05 was considered statistically significant. All
experiments were performed in triplicate.
Results
EGFR signal cascade regulation on DPD protein
expressions
To elucidate the relationship between the EGFR signal
cascade and DPD expression, we first administered
varying concentrations of EGF to PC9 cells (exon19
E746-A750). Western blotting showed EGF administra-
tion induced the phosphorylation of ERK1/2 and the
expressions of Sp1 and DPD were increased dose-
dependently (Fig. 1a). Second, we suppressed EGFR
signal cascade by gefitinib, an EGFR-TKI. Western
blotting showed that phosphorylations of ERK1/2 were
induced by EGF stimulation and were suppressed rapidly
by gefitinib, and EGF-induced expressions of both Sp1
and DPD were also suppressed in a time-dependent
manner (Fig. 1b). To find out whether a reduction of
Sp1 transcriptional activity affected DPD expression,
PC9 cells were treated with mithramycin A, which is an
inhibitor of Sp1. Western blot analysis showed that
mithramycin A inhibited both Sp1 and DPD protein
levels; however, the upstream signaling pathways, includ-
ing ERK1/2 and pERK1/2, were not suppressed (Fig. 1c).
Effect of EGFR-TKI and mithramycin a on Sp1
transcription activity
To test the effect on Sp1 transcriptional activity, PC9
cells were treated with gefitinib and mithramycin A.
Extracted nuclear protein was examined for its Sp1
DNA binding activity by using a Trans AM Sp1 Kit. Sp1
transcription activity was suppressed compared with the
baseline activity level using the two drugs (p < 0.05)
(Fig. 1d).
Comparison of the EGF effect in EGFR-mutated and
-non-mutated NSCLC cell lines
To compare the effect of EGF in differential mutant
types of NSCLC cell lines, EGF of 10 ng/ml was admin-
istrated to each cell line for 20 min (Fig. 2a). In EGFR
mutant NSCLC cell lines (PC9, HCC827, and H1975),
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DPYD mRNA levels were significantly increased after
EGF administration (p < 0.05). On the other hand, DPDY
mRNA levels of EGFR in the wild-type cell lines (H1437,
H1299) were not influenced by EGF treatment.
Comparison of the Gefitinib or mithramycin a effects in
EGFR-mutated and -non-mutated NSCLC cell lines
We next investigated the effects of signal cascade inhibitors
gefitinib and mithramycin A in EGFR-mutated and -non-
mutated NSCLC cell lines. NSCLC cell lines were treated
with gefitinib (1 μM) or mithramycin A (50 nM) for 24 h
followed by stimulation with 10 ng/ml EGF for 20 min. As
shown in Fig. 2b, gefitinib treatment suppressed EGF-
induced ERK1/2 phosphorylation and both Sp1 and DPD
expression only in gefitinib-sensitive NSCLC cell lines PC9
and HCC827. H1975 has an acquired resistance mutation,
T790M, against gefitinib treatment.
Figure 2c shows that ERK1/2 and pERK1/2 upstream sig-
nals of the EGFR cascade were not affected by mithramycin
A. Interestingly, Sp1 and DPD were inhibited only in EGFR
mutant cells.
Comparison of apoptosis after treatment with Gefitinib/
mithramycin a in EGFR-mutated and -non-mutated NSCLC
cell lines
To evaluate the effect of gefitinib and mithramycin A on
cellular apoptosis, we treated cells with gefitinib (1 μM)
and mithramycin A (50 nM) for 24 h. Extracted cell
lysates were evaluated by ELISA using a Cell Death De-
tection ELISAPlus Kit. In wild-type cells (H1299, H1437)
the inhibitors had little effect on apoptosis. In contrast,
the apoptotic reaction increased in EGFR-mutated cell
lines treated with gefitinib, except cell line H1975 with
the T790M mutation. Mithramycin A increased apop-
tosis in all EGFR-mutated cell lines (Fig. 3).
Fig. 1 a PC9 cells were incubated with various concentrations of EGF, and whole cell lysates were extracted and were examined by immunoblot
analysis. b, c. Effects of gefitinib and mithramycin A on ERK, Sp1, and DPD in immunoblot analysis. PC9 cells were pretreated with gefitinib (1 μM) or
mithramycin A (50 nM) before administration of 10 ng/ml EGF. After treatment, whole cell lysates were extracted and examined by western blotting.
Results are representative of two independent experiments. d PC9 cells were stimulated with inhibitors, and nuclear extracts were prepared to detect
the Sp1/DNA interaction by a Trans AM Sp1 kit. The experiment was performed in triplicate. *, p-value < 0.05
Tominaga et al. BMC Cancer  (2016) 16:354 Page 4 of 9
Fig. 2 a Comparisons of DPD mRNA expression with EGF administration in NSCLC cell lines. Serum-free cells were incubated in the presence or
absence of 10 ng/ml EGF. After that, DPD mRNA levels were quantified by RT-PCR. The experiment was performed in triplicate. *, p < 0.05 b, c NSCLC
cell lines were treated with gefitinib (1 μM) or mithramycin A (50 nM) for 24 h followed by stimulation with 10 ng/ml EGF for 20 min. Extracted lysates
were examined by western blotting. Results are representative of two independent experiments
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Comparison of the growth inhibition after combination
treatment with FU and Gefitinib/mithramycin a in
EGFR-mutated and -non-mutated NSCLC cell lines
To elucidate the effect of gefitinib or mithramycin A
with FU in each cell line, we treated cells with combina-
tions of FU (10 μM) and gefitinib (1 μM) or mithramy-
cin A (50 nM). In PC9 and HCC827 cells, the levels of
cell viability were significantly lower in the combination
treatments including gefitinib and mithramycin A com-
pared with FU treatment alone (Fig. 4). In H1975 cells,
which have the T790M mutation, the IC50 values were
lower only for the combination of mithramycin A and
FU. The other two wild-type cell lines showed no differ-
ences when combining drugs. Cell viabilities using 5-FU,
gefitinib, and mithramycin A were not different from the
combination of two drugs (5-FU and gefitinib, or 5-FU
and mithramycin A).
Discussion
The present study clearly showed crosstalk among the
EGFR cascade, transcription factor Sp1, and DPD
expression in NSCLC cell lines. Using PC9 cells, EGF
administration significantly increased DPD protein levels
in a dose-dependent manner. Accordingly, gefitinib, an
EGFR-TKI, inhibited the phosphorylation of ERK1/2 and
decreased ERK1/2, Sp1, and DPD protein levels. The
regulation of DPD by the above-described EGFR signal
induction and inhibition indicated that the EGFR signal
cascade directly regulates DPD expression. On the other
hand, mithramycin A, a G-C specific DNA binding drug
that can bind the consensus sequence of the Sp1 binding
element [28], decreased Sp1 and DPD protein levels
without inhibiting the phosphorylation and protein
levels of ERK1/2. Therefore, we assessed that Sp1 is a
principal candidate for the EGF-induced transcriptional
regulator of DPD.
The activation of EGFR to the DPD cascade is differ-
ent between EGFR-mutated and -non-mutated cell lines;
EGFR mutant cells cause both ligand-independent and
ligand-dependent activation of Sp1 to DPD signals. Con-
sistent with a report by Sordella and colleagues showing
that the receptor and downstream signaling are constitu-
tively activated only in EGFR mutant cells [29], both Sp1
and DPD proteins were increased in EGFR-mutated cell
lines compared to the wild-type under normal conditions
(Fig. 2a). In addition, EGF administration increased DPYD
mRNA expression only in EGFR-mutated cells. These
results support the theory that EGF treatment induces
higher and more consistent activation in mutant EGFRs
than in wild-type EGFRs in NSCLC cell lines [1, 30].
Consistently, western blot analysis showed that gefitinib
decreased ERK1/2 signaling with the suppression of the
protein levels of Sp1 and DPD only in EGFR-mutated cells
(Fig. 2b, c). In addition, the usage of mithramycin A
showed that DPD suppression only occurred in EGFR-
mutated cells, but not in wild-type cells. The two drugs also
increased apoptosis in EGFR mutant cell lines (Fig. 3).
In this study, we examined H1975, another EGFR-
mutated cell line that contains the T790M mutation and
is resistant to gefitinib treatment (Additional file 2: Table
S1). As expected, in western blot analysis, gefitinib did
not decrease the DPD expression. Instead, mithramycin
A clearly inhibited Sp1 and DPD expressions. Accord-
ingly, in drug combination assays, gefitinib and FU
showed additive anticancer effects in EGFR-mutated
PC9 cells, but not in EGFR-resistant H1975 cells. On the
other hand, mithramycin A and FU showed additive
anticancer effects in all EGFR-mutated cells regardless of
the T790M mutation.
The present results elucidated a relationship between
clinical outcomes and the biology of EGFR-mutated
NSCLC. First, in our previous histopathological study, we
showed that adenocarcinoma in situ, previously classified
as bronchioloalveolar carcinoma, has significantly higher
EGFR mutation frequency and DPYD mRNA levels than
other histological types [24]. The presently identified
Fig. 3 Apoptosis was evaluated by ELISA using a Cell Death Detection ELISAPlus Kit (Roche Applied Science). To evaluate the effect of gefitinib
and mithramycin A on cell apoptosis, we treated cells with gefitinib (1 μM) and mithramycin A (50 nM) for 24 h. Extracted cell lysates were
evaluated by ELISA. In wild-type cells (H1299, H1437) there was little effect of the inhibitors on apoptosis. By contrast, apoptosis increased in
EGFR-mutated cell lines treated with gefitinib, except for H1975 with the T790M mutation. Mithramycin A increased apoptosis in all
EGFR-mutated cell lines. Gef, gefitinib; Mit A, mithramycin A. The experiment was performed in triplicate. *, p < 0.05
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signal regulation supports our previous proposal that
invasive adenocarcinoma and adenocarcinoma in situ
might have different biological properties due to different
EGFR signal cascade regulation and DPD activity [24].
Second, the relationship between EGFR mutation status
and high DPD expression might serve as a predictor of
drug sensitivity. Because DPD is a 5-FU degradation
enzyme, EGFR-mutated tumors might resist DIF because
of high DPD. Conversely, EGFR wild-type tumors might
be sensitive to DIF because of low DPD. Consistent with
this, it has been reported that EGFR wild-type tumors
have higher sensitivity to uracil-tegafur than EGFR mutant
tumors [23]. Third, the present results might affect the
treatment strategy for EGFR-TKI-resistant tumors. Gefi-
tinib and 5-FU additively reduced PC9 and HCC827 cell
survival, suggesting that gefitinib treatment might increase
the effect of 5-FU on EGFR-TKI-sensitive tumors, possibly
from DPD suppression via EGFR signal cascade inhibition.
In addition, mithramycin A could enhance the 5-FU effect
on EGFR-TKI-resistant tumors via direct Sp1 suppression.
Mithramycin A and 5-FU-related drugs might be another
option for EGFR-TKI-resistant NSCLC treatment.
The limitation of the present study is that the cis-
regulatory element of DPD contains several transcription
factor-binding sites aside from Sp1, including AP, Egr, and
NF-kB [26]. Fig. 4 shows that cell viability after treatment
of 5-FU plus gefitinib was relatively high compared with
treatment of 5-FU plus mithramycin A in PC9 and
HCC827 cells. This implies the existence of some unknown
transcriptional regulation present in this cascade, especially
in EGFR mutant-type tumors (Additional file 1: Figure S1).
Further analysis of other transcriptional regulation mecha-
nisms might be necessary to elucidate the mechanisms of
EGFR signal regulation for DPD expression. In the wild-
type cell lines, 5-FU monotherapy did not affect cell
survival in H1437 cells, even with low expression of DPD.
In fact, the IC50 with 5-FU was higher in H1437 than in
H1299, even though they have the same EGFR wild-type
Fig. 4 In combination assays, NSCLC cell lines were seeded in 96-well plates at a density of 105/well with culture medium for 24 h. The cell lines were
treated with FU (10 μM) alone or FU plus gefitinib (1 μM)/mithramycin A (50 nM) for another 24 h at 37 °C in a 5 % CO2 atmosphere. After that, WST-1
was added to each well and incubated for 2 h at 37 °C before measuring absorbance at 490 nm with a Multiskan JX Spectrum instrument. The
experiments were performed in triplicate. * p < 0.05. Mit A, mithramycin A
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status (Additional file 2: Table S1). This is unsurprising
because H1437 has the MEK1 exon2 mutation (Q56P
substitution) [31], and MEK-1 signal suppression increases
5-FU sensitivity [32]. These reports and the present results
indicate that continuous MEK-1 expression in H1437
results in 5-FU resistance, possibly because of a DPD-
independent mechanism in this wild-type cell line.
Conclusion
In conclusion, we have shown crosstalk among the EGFR
cascade and Sp1 and DPD expressions in EGFR mutant cell
lines. EGF-induced Sp1 up-regulation resulted in both
DPYD mRNA and DPD protein expressions. Combination
chemotherapy of 5-FU and EGFR-TKI additively sup-
pressed cancer cell survival in EGFR-mutant cell lines. In
particular, 5-FU and mithramycin A induced cytotoxicity in
EGFR-resistant cell lines. Further studies are necessary to
elucidate the detailed mechanism of EGFR cascade regula-
tion of DPD expression, which may lead to new therapeutic
strategies against NSCLC.
Additional files
Additional file 1: Figure S1. Schematic diagrams of the signal cascade
of EGF-induced DPD expression of EGFR-mutated type cells.
TF, transcription factor; Mit A, mithramycin A. (JPG 130 kb)
Additional file 2: Table S1. Effects of 5-FU, gefitinib, and mithramycin
A on cell proliferation in NSCLC cell lines. Cells were incubated with
various concentrations of 5-FU for 72 h, and cell viability was examined
by WST-1 assay. The IC50 values of these drugs were calculated for each
cell line. Cell viability of the control group (DMSO) was set at 100 %.
Values are means from three samples from one representative
experiment. (XLSX 9 kb)
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